Jubilant

Empowering CX in India: Driving Growth and Efficiency for Global Brands through CX Innovation

Retrieved on: 
Wednesday, May 17, 2023
CXO, Emerging, Customer experience, Tech Talk Live, Strategic partnership, Customer, Center for Digital Technology and Management, Digital, SVP, Elan Media Partners, Max Life Insurance, Jubilant, The Body Shop, AVP, Digital transformation, PYP, CRM, Entrepreneurship, Information officer, Conference, Chief technology officer, MEA, Ministry of External Affairs, NCR, Government, Ministry, Tata Communications, Schneider Electric, Foreign policy, Nature, ITC Limited, Rights, CX, Intangibles, ServiceNow, National Digital Information Infrastructure and Preservation Program, Management, Head, Flipkart, Uniphore, Exotel, Genesys

The World CX Summit – India was designed to offer an exceptional learning opportunity for the attendees with informative discussions, inspiring presentations, highlighting the latest trends and techniques in the field of CX innovation.

Key Points: 
  • The World CX Summit – India was designed to offer an exceptional learning opportunity for the attendees with informative discussions, inspiring presentations, highlighting the latest trends and techniques in the field of CX innovation.
  • This event has previously been held in various parts of the world with great success.
  • The World CX Summit - Delhi wrapped up with a One-day power packed conference.
  • In this panel the speakers highlighted the challenges faced by companies in improving customer experience.

U.S PET Imaging Market Summary Report 2023: PET Prostate Scan Volumes Saw Robust Growth in 2022 - ResearchAndMarkets.com

Retrieved on: 
Thursday, April 6, 2023
Radiology, Health, Medical Devices, GE HealthCare, F-18 FDG, CT, Bed, Original equipment manufacturer, Cancer, GE, PET, Radiopharmaceutical, Cardinal Health, Siemens Healthineers, Hospital, Patient, Canon Medical Systems Corporation, PET/CT, PET/MR, Diagnosis, Philips, Cardiology, OEM, Neurology, Medical imaging, Jubilant

This '2023 PET Imaging Market Summary Report' summarizes the results from the Medical Information Division's 2022 PET Census of hospital and non-hospital facilities performing PET imaging in the United States.

Key Points: 
  • This '2023 PET Imaging Market Summary Report' summarizes the results from the Medical Information Division's 2022 PET Census of hospital and non-hospital facilities performing PET imaging in the United States.
  • PET prostate scan volumes grew 46% year-over-year, showing an increase of 3 percentage points to produce 9% of the overall procedure mix by study type, according to the 2023 PET Market Summary Report.
  • After a 12.2% increase in overall PET scan volume in 2021, PET scan volume remained flat year over year in 2022.
  • The '2023 PET Imaging Market Summary Report' monitors trends in PET scan utilization, the adoption of fixed PET scanners (e.g., PET-only, PET/CT, and PET/MR), the use of mobile PET services, purchase plans, and radiopharmaceutical use.

PET Prostate Scan Volumes See Robust Growth in 2022 according to IMV's 2023 PET Market Summary Report

Retrieved on: 
Wednesday, April 5, 2023
Science, IMV, Original equipment manufacturer, PET, Cardinal Health, Hospital, Philips, OEM, Medical imaging, Canon, Jubilant

ARLINGTON, Va., April 5, 2023 /PRNewswire-PRWeb/ -- IMV's 2023 PET Market Summary Report explores market trends in U.S. hospitals and imaging centers, including procedure volume, manufacture-installed base features and share, the use of OEM vs. third-party service providers, purchase plans, brand loyalty, radiopharmaceutical usage and site operations characteristics. The report was published in March 2023 and is based on responses from 386 radiology/departmental administrators and clinicians who participated in IMV's nationwide survey from August 2021-September 2022. Vendors covered in this report include Bracco, Canon, Cardinal Health, GEHC, Jubilant, Philips, Siemens and SOFIE. The finding summaries follow.

Key Points: 
  • PET prostate scan volumes increased 46% year-over-year, according to a recent IMV market research report.
  • The report was published in March 2023 and is based on responses from 386 radiology/departmental administrators and clinicians who participated in IMV's nationwide survey from August 2021-September 2022.
  • PET prostate scan volumes increased 46% year-over-year, showing an increase of 3 percentage points to 9% of the overall procedure mix by study type, according to the newly published IMV 2023 PET Market Summary Report.
  • After a 12.2% increase in overall PET scan volume in 2021, PET scan volume remained flat year-over-year in 2022.

Global Liquid Carbon Dioxide (CO2) Market Report 2023: Featuring Punjab Carbonic, SICGIL India, AlcoBioFuel Bio-Refinery, CF Fertilisers & More - ResearchAndMarkets.com

Retrieved on: 
Thursday, March 16, 2023
Retail, Chemicals, Plastics, Manufacturing, Food, Beverage, Carbon, Air Products, Heat, United Kingdom, Snow, Belgium, Fermentation, Water, Jubilant, BIG, International trade, Chemical substance, Liquid carbon dioxide, Database, Food packaging, Dry ice, Pittsburgh Food & Beverage Company, CO2, Methane, Drink, Container deposit legislation in the United States, Beer, Lead, Linde plc, Coal, Industrial gas, Bottled water, Natural gas, Health care, Others

This region accounted for a market share of about 50% of the global Liquid Carbon Dioxide market in 2021.

Key Points: 
  • This region accounted for a market share of about 50% of the global Liquid Carbon Dioxide market in 2021.
  • To classify and forecast the Global Liquid Carbon Dioxide market based on end-use and regional distribution.
  • To examine global competitive developments such as new capacity expansions, mergers & acquisitions, etc., of the Liquid Carbon Dioxide market.
  • In this report, Global Liquid Carbon Dioxide market has been segmented into following categories, in addition to the industry trends which have also been detailed below:

Jubilant HollisterStier Announces New President and Upcoming Availability of Expanded Production Capacity for Sterile Injectables

Retrieved on: 
Thursday, March 16, 2023
Research, Medical Devices, Medical Supplies, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Lonrho, Jubilant, Furman University, University, Business, Widener University Commonwealth Law School, Partnership, Darla Moore School of Business, Journal of International Business Studies, USD, JHS, Government, Wharton School of the University of Pennsylvania, Marketing, GSK plc, Privacy and the US government, Pharmaceutical industry, Pharma, Chemistry

Jubilant HollisterStier (JHS), a leading US-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products announces the appointment of Chris Preti as President.

Key Points: 
  • Jubilant HollisterStier (JHS), a leading US-based pharmaceutical contract manufacturer of sterile fill/finish injectables, ampules, ophthalmics and sterile liquid products announces the appointment of Chris Preti as President.
  • Chris Preti has 25 years of varied pharmaceutical experience in research and development, marketing and sales, and operations, including positions of increasing responsibility at Glaxo SmithKline and HollisterStier Allergy, where he was most recently President.
  • As previously announced in May 2022, Jubilant HollisterStier’s expansion plan that is investing ~285 million (USD) to double its capacity for fill and finish of sterile injectables at its Spokane, Washington facility, is progressing well.
  • Chris Preti commented, “This is an exciting time to join Jubilant HollisterStier, as the company continues to expand its capacity to address growing industry demand for the high-quality services we provide.

Jubilant Therapeutics Inc. receives Orphan Drug Designation for the PRMT5 inhibitor - JBI-778 for the treatment of Glioblastoma Multiforme (GBM)

Retrieved on: 
Monday, February 13, 2023
Brain, ODD, AML, Glioblastoma, Therapy, SCLC, GBM, Safety, Carcinoma, US FDA, Food, PRMT5, Person, Plasma, Disease, Jubilant, FDA, US, Acute myeloid leukemia, Neoplasm, Pharmaceutical industry

JBI-778 is an oral, brain penetrant and substrate-competitive protein arginine methyl transferase 5 (PRMT5) inhibitor for the treatment of tumors with brain metastases and primary brain tumors including high-grade glioma.

Key Points: 
  • JBI-778 is an oral, brain penetrant and substrate-competitive protein arginine methyl transferase 5 (PRMT5) inhibitor for the treatment of tumors with brain metastases and primary brain tumors including high-grade glioma.
  • "JBI-778 is our highly differentiated, substrate competitive PRMT5 inhibitor in development for both systemic and brain tumors with certain genetic signatures.
  • It is the second clinical stage oral drug candidate that has emerged from the TIBEO discovery engine," said Syed Kazmi, Chief Executive Officer, Jubilant Therapeutics Inc.
  • He further added, "JBI-778's differentiated profile compared to other PRMT5 inhibitors in development addresses safety issues of first-generation PRMT5 inhibitors.

Canadian Nuclear Laboratories and Jubilant Radiopharma to Collaborate on the Development of Novel Alpha Radiopharmaceuticals

Retrieved on: 
Friday, February 3, 2023
Nuclear medicine, Nuclear, Atomic energy, Waste management, National Nuclear Laboratory, CNL, Business development, CNRI, Jubilant, Actinium-225, Radiobiology, Radiopharmaceutical, Science and technology, Good laboratory practice, Center for Drug Evaluation and Research, SMR, Research, Atomic Energy of Canada Limited, Medical imaging, Pharmaceutical industry, Science, Health

CHALK RIVER, Ontario, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, is pleased to announce that it will collaborate with Jubilant Radiopharma, an international leader in radiopharmaceuticals, on the development of novel alpha radiopharmaceuticals.

Key Points: 
  • CHALK RIVER, Ontario, Feb. 03, 2023 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canada’s premier nuclear science and technology organization, is pleased to announce that it will collaborate with Jubilant Radiopharma, an international leader in radiopharmaceuticals, on the development of novel alpha radiopharmaceuticals.
  • The new research cooperation with Jubilant represents the first project in the new CNRI-H program, which is designed to accelerate the development of targeted radiopharmaceuticals in Canada through joint research projects related to health sciences, radiobiology and medical isotope development.
  • “CNL launched CNRI-H to advance the development of targeted radiopharmaceuticals in Canada through collaborations with pioneering health sciences organizations.
  • “Canadian Nuclear Laboratories is uniquely equipped in this country to undertake research using these alpha-emitting isotopes,” commented George Baidoo, CNL’s Technical Director of Health in Business Development.

Life Molecular Imaging and Jubilant Radiopharma announce Neuraceq® availability in Southeast United States

Retrieved on: 
Tuesday, January 10, 2023
Partnership, Drug development, Government budget balance, Research, LMI, Brain, Alzheimer's disease, Dementia, Disease, Patient, SPECT, Physician, PET, Jubilant, Neurodegeneration, Medical imaging

BOSTON, Jan. 10, 2023 /PRNewswire-PRWeb/ -- Life Molecular Imaging (LMI) and Jubilant Radiopharma announce today that both companies have entered into a strategic partnership and licensing agreement providing Jubilant Radiopharma with rights to manufacture and distribute Neuraceq® in the Southeast Region of United States. Jubilant Radiopharma will manufacture Neuraceq® at their PET cyclotron facility which has an adjoining SPECT radiopharmacy in Norcross, GA. The first doses will be available from January 18th, 2023.

Key Points: 
  • BOSTON, Jan. 10, 2023 /PRNewswire-PRWeb/ -- Life Molecular Imaging (LMI) and Jubilant Radiopharma announce today that both companies have entered into a strategic partnership and licensing agreement providing Jubilant Radiopharma with rights to manufacture and distribute Neuraceq® in the Southeast Region of United States.
  • Jubilant Radiopharma will manufacture Neuraceq® at their PET cyclotron facility which has an adjoining SPECT radiopharmacy in Norcross, GA.
  • "With the addition of Jubilant's Norcross Radiopharmacy to our distribution network, Life Molecular Imaging continues to expand the availability of Neuraceq®, an important diagnostic imaging tool for the detection of beta-amyloid plaques in the brain.
  • "It is a great pleasure to have signed this important manufacturing and distribution agreement with Life Molecular Imaging" – declares Renato Leite, President at Jubilant Radiopharmacies.

Jubilant Therapeutics Inc. receives Orphan Drug Designation for JBI-802 for Acute Myeloid Leukemia (AML) and Small Cell Lung Cancer (SCLC)

Retrieved on: 
Thursday, January 5, 2023
Clinical trial, US FDA, ODD, Food, MYC, Squamous cell carcinoma, Therapy, Phenotype, Acute myeloid leukemia, Person, Disease, Leukemia, Patient, RCOR1, Degenerative disease, Therapeutic index, MPN, Diamond–Blackfan anemia, FDA, AML, Wilms' tumor, US, Jubilant, Thrombocythemia, Pharmaceutical industry, Mobile phone, SCLC

BEDMINSTER, N.J., Jan. 5, 2023 /PRNewswire/ -- Jubilant Therapeutics Inc ., a clinical stage biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced that the United States Food and Drug Administration (US FDA) has granted Orphan Drug Designation for JBI-802 for the treatment of small cell lung cancer (SCLC) and acute myeloid leukemia (AML).

Key Points: 
  • BEDMINSTER, N.J., Jan. 5, 2023 /PRNewswire/ -- Jubilant Therapeutics Inc ., a clinical stage biopharmaceutical company advancing small molecule precision therapeutics to address unmet medical needs in oncology and autoimmune diseases, today announced that the United States Food and Drug Administration (US FDA) has granted Orphan Drug Designation for JBI-802 for the treatment of small cell lung cancer (SCLC) and acute myeloid leukemia (AML).
  • This unique profile has shown synergistic anti-tumor activity and it is expected to overcome tolerability limitations of first-generation, single target epigenetic modulators.
  • "JBI-802 is the lead product candidate from our TIBEO (Therapeutic Index and Brain Exposure Optimization) Discovery Engine.
  • It is our unique approach of structure-based drug design to generate novel pharmacophores with improved target product profile compared to existing agents.

Jubilant Therapeutics Inc. to Present at Credit Suisse and Jefferies Investor Conferences

Retrieved on: 
Wednesday, November 2, 2022
Credit, PRMT5, Therapeutic index, Conference, Cancer, IND, Company, Therapy, Degenerative disease, Patient, Credit Suisse, Jubilant, Pharmaceutical industry

Its advanced structure based discovery engine, TIBEO (Therapeutic Index and Brain Exposure Optimization), has been validated through successful partnerships including with Blueprint Medicines.

Key Points: 
  • Its advanced structure based discovery engine, TIBEO (Therapeutic Index and Brain Exposure Optimization), has been validated through successful partnerships including with Blueprint Medicines.
  • The Company's pipeline, consists of a first-in-class dual epigenetic modifier, JBI-802, currently in a Phase I/II clinical trial to treat solid tumors, a novel brain-penetrant modulator of PRMT5 for which an IND has been accepted, brain penetrant and gut restrictive PDL1 inhibitors, as well as PAD4 inhibitors for oncology and inflammatory indications.
  • The Company is headquartered in Bedminster, New Jersey and guided by globally renowned scientific advisors.
  • For more: www.jubilanttx.com , Twitter @JubilantTx , LinkedIn